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At the present time, rejection is the most frequent cause of graft dysfunction in liver 
transplantation. Differential diagnosis between this and other possible causes of 
dysfunction—preservation injury, vascular, biliary, viral—may well be difficult, as the 
clinical and analytical findings are often similar; moreover, no markers specific to 
rejection are available, and histological studies are necessary for a definitive diagnosis. 
For this reason, markers indicating activity within the immune system need to be 
established so as to provide a more specific means of distinguishing rejection from 
other causes of graft dysfunction. 
 
The immune response to an allograft is complex, and the intricate mechanisms 
regulating it are still not entirely understood. Nevertheless, several specialists have 
drawn connections among changes in the lymphocyte subpopulations,1,2 rises in the 
interleukin-2 levels, expression of the interleukin-2 receptor,3,4 and alteration in the 
expression of antigens belonging to class II in the greater complex of 
histocompatibility, with rejection of the allograft.5 
 
Leukotriene B4 (LTB4) is a derivative of the metabolism of arachidonic acid via 5-
lipoxygenase, whose in vitro behaviour is to encourage rejection by favoring leukocyte 
aggregation, proliferation of T lymphocytes, interleukin-1 and -2 secretion, and the 
development of "natural killer" cell subpopulations.6-8 This study examines the role of 
LTB4 in mediating the immune response to the hepatic allograft in order to assess its 
usefulness in early diagnosis of rejection. 
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MATERIALS AND METHODS 
 
In this study we performed orthotopic liver tiansplant on five mongrel dogs weighing 
between 20 and 30 kg. We followed the technique described by Starzl et al,9-11 with 
some modifications. For preservation, Euro-Collins solution was used at 4°C, the cold 
ischemia time being 87 ± 21 minutes. 
 
In the anhepatic phase, spontaneous femoro-porto-jugular by-pass was performed. 
After the portal venous system had been revascularized, end-to-end arterial 
anastomosis was performed between the celiac axis of the donor and recipient. In two 
out of five animals this anastomosis was performed end to side between the hepatic 
artery of the donor and the exit of the celiac axis in the recipient. Biliary reconstruction 
was carried out by means of cholecystoduodenostomy. In all cases, there was 
autotransfusion of a unit of blood extracted a week before the operation. None of the 
animals were given immunosuppressives. Percutaneous liver biopsy was performed 
systematically on the fourth postoperative day. 
 
Blood samples were taken at the following stages during the study: one week before 
surgery (basal), after endotracheal intubation before laparotomy, 8 hours after 
revascularization of the graft through the portal veins, and every day for the rest of the 
postoperative period. At each stage, the levels of the following were noted: glutamic-
oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), alkaline 
phosphatase, gamma-glutamic transpeptidase (gamma-GT), bilirubin, and LTB4. 
 
Levels of LTB4 were calculated by radioimmunoassay. Antibody anti-LTB4 was 
obtained from Advanced Magnetic Inc. (Cambridge, Mass). 
 
The results were expressed as mean ± SEM. The mean of the five basal dogs were used 
as control parameters. Observations were compared using Student's t test for paired 
samples. The level of significance was set at P < .05. 
 
 
 
 
RESULTS 
 
The five animals survived for an average of 6.6 days (range 4 to 8). In all cases, 
anatomical and pathological examinations revealed the presence of major rejection. In 
two animals there were clear anatomical signs of rejection on the fourth day. Both 
animals survived fewer than 6 days. 
 
LTB4 levels in the five dogs showed a variable development pattern. Nonetheless, our 
findings showed a tendency for the mean levels of this parameter to increase as the 
postoperative period progressed (Fig 1). A significant difference exists between the 
base level and the reading at 24 (P < .001), 48 (P < .001), and 72 (P < .01) hours before 
decease. The other parameters investigated are enumerated in Table 1. 
 
DISCUSSION 
 
This study analyses for the first time the behaviour (in vivo) of LTB4 in a model of 
hepatic rejection without immunosuppression. The findings described here confirm 
the pro-rejection character attributed to this substance by in vitro studies.6-8 This is a 
new step toward gaining an understanding of the intricate mechanisms of 
immunological regulation. Our work confirms a progressive rise in LTB4 levels as 
rejection becomes established. 
 
This parameter rises earlier than the other parameters generally used to evaluate 
rejection (Table 1), which means that it could be used as a specific and early marker for 
rejection. 
 
The inhibition of the synthesis of this compound by blocking the metabolism of 
arachidonic acid via 5-lipoxygenase has been the subject of previous studies,12-14 and 
may well offer new therapeutic alternatives in the prevention and treatment of 
rejection. 
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Figure 1. Mean trend of LTB4 
 
 
 
 
 
 
 
 
 
Table 1. Mean Values of Hepatic Function Parameters 
 Basal Day 1 Day 4 Day 7 
LTB4 45.4 81.9 131.5 212.7 
GOT 14 1722 106 493 
Alkaline P 54 79 825 6671 
Bilirubin 0.18 0.50 1.31 1.61 
 
